BioCryst Pharmaceuticals BCRX Pre-Tax Income (Domestic)
Pre-Tax Income (Domestic) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's pre-tax income (domestic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's pre-tax income (domestic)?
- BioCryst Pharmaceuticals (BCRX) reported pre-tax income (domestic) of $43.16M in Q4 2025.
- How has BioCryst Pharmaceuticals's pre-tax income (domestic) changed year-over-year?
- BioCryst Pharmaceuticals's pre-tax income (domestic) increased by 376.2% year-over-year, from -$15.63M to $43.16M.
- What is the long-term trend for BioCryst Pharmaceuticals's pre-tax income (domestic)?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's pre-tax income (domestic) has grown at a 2.0% compound annual growth rate (CAGR), from -$159.63M to $172.64M.
- What does pre-tax income (domestic) mean?
- Pre-tax income or loss generated specifically from domestic business operations, excluding discontinued operations and tax provisions. This metric isolates the profitability of the company's home-market activities. It is critical for evaluating the core operational performance and tax-adjusted earnings potential within the primary regulatory and economic environment.